We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Mathematical Model Devised for Curing More Cervical Cancer Patients

By HospiMedica International staff writers
Posted on 24 Feb 2010
Cervical cancer is curable when detected early. More...
But in one-third of cases, the tumor responds poorly to therapy or recurs later, when cure is much less likely. A more rapid identification of nonresponding tumors may be possible using a new mathematical model.

The model, devised by researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James; Columbus, USA), utilizes information from magnetic resonance imaging (MRI) scans taken before and during therapy to monitor changes in tumor size. That information is plugged into the model to predict whether a specific case is responding well to treatment. If not, the patient can be changed to a more aggressive or experimental therapy midway through treatment, something not possible now.

The study, published in the February 1, 2010, issue of the journal Cancer Research, uses MRI scans and outcome information from 80 cervical cancer patients receiving a standard course of radiation therapy designed to cure their cancer. "The model enables us to better interpret clinical data and predict treatment outcomes for individual patients,” said lead investigator Dr. Jian Z. Wang, assistant professor of radiation medicine and a radiation physicist at the OSUCCC-James. "The outcome predictions presented in this paper were solely based on changes in tumor volume as derived from MRI scans, which can be easily accessed even in community hospitals. The model is very robust and can provide a prediction accuracy of 90% for local tumor control and recurrence.”

An advantage of the new model, according to first author Zhibin Huang, is its use of MRI data to estimate three factors that play key roles in tumor shrinkage and that vary from patient to patient--the proportion of tumor cells that survive radiation exposure, the speed at which the body removes dead cells from the tumor, and the growth rate of surviving tumor cells.

The model is applicable to all cervical cancer patients, and the investigators are developing a model that can be applied to other cancer sites, according to Dr. Wang. Co-author Dr. Nina A. Mayr, professor of radiation medicine at Ohio State, noted that the size of cervical tumors is currently estimated by touch, or palpation, which is frequently imprecise. Furthermore, shrinkage of a tumor may not be apparent until months after therapy has ended.

Other clinical factors currently used to predict a tumor's response to therapy include the tumor's stage, whether it has invaded neighboring lymph nodes and its microscopic appearance. "Our kinetic model helps us understand the underlying biological mechanisms of the rather complicated living tissue that is a tumor,” Dr. Wang concluded. "It enables us to better interpret clinical data and predict treatment outcomes, which is critical for identifying the most effective therapy for personalized medicine.”

Related Links:

Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital




Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Glucose Meter
StatStrip®
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: 123RF

AI Platform Screens for Amyloid Cardiomyopathy Using ECG Images

Amyloid cardiomyopathy is a heart disease caused by deposits of misfolded proteins in the cardiac muscle. It is often missed until patients develop serious complications such as heart failure.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.